Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

Bibliographic Details
Main Authors:	Harmon, Charles S., DePrimo, Samuel E., Figlin, Robert A., Hudes, Gary R., Hutson, Thomas E., Michaelson, M. Dror, Négrier, Sylvie, Kim, Sindy T., Huang, Xin, Williams, J. Andrew, Eisen, Tim, Motzer, Robert J.
Format:	Online
Language:	English
Published:	Springer Berlin Heidelberg 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889677/

Similar Items

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
by: Patil, S, et al.
Published: (2012)

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
by: DePrimo, Samuel E, et al.
Published: (2007)

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma
by: Cella, David, et al.
Published: (2014)

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib
by: Keyvanjah, Kiana, et al.
Published: (2012)

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
by: Motzer, Robert J., et al.
Published: (2014)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
by: Hutson, T E, et al.
Published: (2014)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
by: Donskov, Frede, et al.
Published: (2015)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
by: Molina, Ana M., et al.
Published: (2010)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
by: Rini, Brian I., et al.
Published: (2011)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
by: Cella, D, et al.
Published: (2012)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
by: Zurita, A J, et al.
Published: (2015)

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
by: Molina, Ana M., et al.
Published: (2013)

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
by: Harmon, Charles S, et al.
Published: (2011)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
by: Motzer, R J, et al.
Published: (2013)

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
by: Voss, Martin H, et al.
Published: (2016)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)

Metastatic collecting duct carcinoma of the kidney treated with sunitinib
by: Tazi, El Mehdi, et al.
Published: (2011)

A Case of Metastatic Adamantinoma That Responded Well to Sunitinib
by: Liman, Andrew D., et al.
Published: (2016)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
by: Bracarda, S, et al.
Published: (2012)

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer
by: Rossi, E, et al.
Published: (2012)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
by: Ordu, Çetin, et al.
Published: (2016)

Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example
by: Burotto, Mauricio, et al.
Published: (2014)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
by: Beuselinck, B, et al.
Published: (2013)

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment
by: Chara, Luis, et al.
Published: (2011)

Retraction: metastatic collecting duct carcinoma of the kidney treated with Sunitinib
by: Tazi, El Mehdi, et al.
Published: (2011)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
by: Gilabert, M, et al.
Published: (2013)

A case of metastatic renal cell carcinoma treated effectively by gemcitabine and sunitinib
by: Morizane, Shuichi, et al.
Published: (2012)

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
by: Yildiz, Ibrahim, et al.
Published: (2014)

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials
by: Bono, Petri, et al.
Published: (2016)

Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial
by: Cella, David, et al.
Published: (2014)

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
by: Ravaud, A., et al.
Published: (1994)

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
by: Gore, M E, et al.
Published: (2015)

Sunitinib: the antiangiogenic effects and beyond
by: Hao, Zhonglin, et al.
Published: (2016)

Sunitinib Induced Immune Thrombocytopenia
by: Shekarriz, Ramin, et al.
Published: (2015)

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
by: Bharwani, N, et al.
Published: (2014)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
by: Kang, Y-K, et al.
Published: (2013)

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
by: Bamias, A, et al.
Published: (2013)

Sunitinib for advanced renal cell cancer
by: Coppin, Chris
Published: (2008)

Sorafenib and sunitinib: A dermatologist's perspective
by: Pragasam, Vijendran, et al.
Published: (2014)

Combining radiotherapy with sunitinib: lessons (to be) learned
by: Kleibeuker, Esther A., et al.
Published: (2015)